Prognostic	B:C0220901
and	O
therapeutic	O
value	O
of	O
mitochondrial	B:C4045550
serine	I:C4045550
hydroxyl	I:C4045550
-	I:C4045550
methyltransferase	I:C4045550
2	I:C4045550
as	O
a	O
breast	B:C0006142
cancer	I:C0006142
biomarker	B:C0005516
.	O

Mitochondrial	B:C4045550
serine	I:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
(	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
)	O
is	O
a	O
key	O
enzyme	B:C0014442
in	O
the	O
serine	B:C1156644
/	I:C1156644
glycine	I:C1156644
synthesis	I:C1156644
pathway	I:C1156644
.	O

serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
has	O
been	O
implicated	O
as	O
a	O
critical	O
component	O
for	O
tumor	B:C0597032
cell	I:C0597032
survival	B:C0007620
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
evaluate	O
the	O
prognostic	B:C0220901
value	O
and	O
efficiency	O
of	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
as	O
a	O
biomarker	B:C0005516
in	O
patients	O
with	O
breast	B:C0006142
cancer	I:C0006142
.	O

Individual	B:C0237401
and	O
pooled	B:C1257890
survival	B:C0038953
analyses	I:C0038953
were	O
performed	O
on	O
five	O
independent	O
breast	B:C0006142
cancer	I:C0006142
microarray	O
datasets	B:C0150098
.	O

Gene	O
signatures	O
enriched	O
by	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
were	O
also	O
analyzed	O
in	O
these	O
datasets	B:C0150098
.	O

serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
protein	B:C1171362
expression	I:C1171362
was	O
detected	O
using	O
immunohistochemistry	B:C0021044
(	O
immunohistochemistry	B:C0021044
)	O
assay	B:C1510438
in	O
128	O
breast	B:C0006142
cancer	I:C0006142
cases	O
.	O

Gene	B:C0936012
set	I:C0936012
enrichment	I:C0936012
analysis	I:C0936012
revealed	O
that	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
was	O
significantly	O
associated	O
with	O
gene	O
signatures	O
of	O
mitochondrial	B:C1959595
module	I:C1959595
,	O
cancer	B:C1269955
invasion	I:C1269955
,	O
metastasis	B:C4255448
and	O
poor	B:C0243095
survival	I:C0243095
among	O
breast	B:C0006142
cancer	I:C0006142
patients	O
(	O
p<0.05	O
)	O
.	O

The	O
clinical	O
relevance	O
of	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
was	O
validated	O
on	O
immunohistochemistry	B:C0021044
data	O
.	O

The	O
mitochondrial	B:C1657244
localization	I:C1657244
of	O
SHMT2	B:C4045550
protein	I:C4045550
was	O
visualized	O
on	O
immunohistochemistry	B:C0021044
staining	B:C0487602
.	O

Independent	B:C0936012
and	O
pooled	B:C0936012
analysis	I:C0936012
confirmed	O
that	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
expression	B:C1171362
was	O
associated	O
with	O
breast	B:C0006142
cancer	I:C0006142
tumor	O
aggressiveness	O
(	O
TNM	B:C1515169
staging	I:C1515169
and	O
Elson	B:C1527124
grade	I:C1527124
)	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
(	O
p<0.05	O
)	O
.	O

The	O
prognostic	B:C0220901
performance	O
of	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
mRNA	B:C0035696
was	O
comparable	O
to	O
other	O
gene	O
signatures	O
and	O
proved	O
superior	O
to	O
TNM	B:C1515169
staging	I:C1515169
.	O

Further	O
analysis	O
results	O
indicated	O
that	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
had	O
better	O
prognostic	B:C0220901
value	O
for	O
estrogen	B:C0279756
receptor	I:C0279756
(	I:C0279756
ER	I:C0279756
)	I:C0279756
-	I:C0279756
negative	I:C0279756
breast	B:C0006142
cancer	I:C0006142
patients	O
,	O
compared	O
to	O
ER	B:C0279754
-	I:C0279754
positive	I:C0279754
patients	O
.	O

In	O
cases	O
involving	O
stage	B:C2216697
IIb	I:C2216697
breast	I:C2216697
cancer	I:C2216697
,	O
chemotherapy	B:C3665472
significantly	O
extended	B:C0231449
survival	B:C2919552
time	I:C2919552
among	O
patients	O
with	O
high	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
expression	B:C1171362
.	O

These	O
results	O
indicate	O
that	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
may	O
be	O
a	O
valuable	O
prognostic	B:C0220901
biomarker	B:C0005516
in	O
ER	B:C0279756
-	I:C0279756
negative	I:C0279756
breast	B:C0006142
cancer	I:C0006142
cases	O
.	O

Furthermore	O
,	O
serine	B:C4045550
hydroxylmethyltransferase	I:C4045550
2	I:C4045550
may	O
be	O
a	O
potential	O
target	O
for	O
breast	B:C0006142
cancer	I:C0006142
treatment	B:C0087111
and	O
drug	B:C0920472
discovery	I:C0920472
.	O

